NHG-Richtlijnen
NHG-Standaard
M64
3.1
februari 2022
januari 2025
S. Huid en subcutis

Begrippen

Naar Volledige tekst ›

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Voorlichting en niet-medicamenteuze behandeling

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Etiologie en pathofysiologie

Naar Samenvatting ›

Risicofactoren

Naar Samenvatting ›

Prognose

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

KOH-diagnostiek

Naar Samenvatting ›

Geen indicatie aanvullend onderzoek

Naar Samenvatting ›

Kader 1 Afname van materiaal voor een kweek of PCR-test

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Tinea (pedis, manuum, corporis), intertrigo door Candida

Naar Samenvatting ›

Voorlichting en advies

Naar Samenvatting ›
Thuisarts
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›
Medicamenteuze behandeling tinea manuum, tinea corporis en intertrigo
Naar Samenvatting ›
Medicamenteuze behandeling tinea pedis
Naar Samenvatting ›
Praktische adviezen bij tinea (pedis, manuum, corporis) en intertrigo
Naar Samenvatting ›
Medicamenteuze behandeling tinea pedis met mocassinpatroon
Naar Samenvatting ›
Medicamenteuze behandeling recidieven
Naar Samenvatting ›
Combinatiepreparaten corticosteroïd/imidazool
Naar Samenvatting ›

Pityriasis versicolor

Naar Samenvatting ›

Voorlichting en advies

Naar Samenvatting ›
Thuisarts
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Preventie van recidieven

Naar Samenvatting ›

Onychomycosen

Naar Samenvatting ›

Voorlichting en advies

Naar Samenvatting ›
Thuisarts
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›
Orale antimycotica
Naar Samenvatting ›
Lokale antimycotica
Naar Samenvatting ›
Orale antimycotica
Naar Samenvatting ›
Lokale antimycotica
Naar Samenvatting ›
Chemische of chirurgische nagelextractie
Naar Samenvatting ›
Laser en lichttherapie
Naar Samenvatting ›

Diepe dermatomycosen (animale mycosen, tinea capitis en tinea barbae)

Naar Samenvatting ›

Voorlichting en advies

Naar Samenvatting ›
Thuisarts
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Controles

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Referenties

  1. Sillevis Smitt JH, Van Everdingen JJE, Van der Horst HE, Wintzen M, Starink TM, Lambert J. Dermatovenereologie voor de eerste lijn. Een systematische introductie. Houten: Bohn Stafleu van Loghum, 2017.
  2. Van de Lisdonk EH, Van den Bosch WJHM, Huygen FJA, Lagro-Janssen ALM. Ziekten in de huisartspraktijk. Maarssen: Elsevier Gezondheidszorg, 2003.
  3. Nivel Zorgregistraties Eerste Lijn (2019) Ga naar bron
  4. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008;51 Suppl 4:2-15.
  5. Lipner SR, Scher RK. Onychomycosis – clinical overview and diagnosis. J Am Acad Dermatol 2019;80:835-51.
  6. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol 2014;28:1480-91.
  7. Elewski BE, Charif MA. Prevalence of onychomycosis in patiënts attending a dermatology clinic in Northeastern Ohio for other conditions. Archives of Dermatoly 1997;133:1172-3.
  8. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19 Suppl 1:8-12.
  9. Papini M, Piraccini BM, Difonzo E, Brunoro A. Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. Mycoses 2015;58:659-64.
  10. Drakensjo IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005-2009. Medical Mycology 2011;49:484–8.
  11. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004;50:748-52.
  12. Nenoff P, Kruger C, Ginter-Hanselmayer G, Tietz HJ. Mycology–an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. Journal of the German Society of Dermatol 2014;12;3;188-210.
  13. Korstanje MJ, Staats CG. Tinea capitis in Northwestern Europe 1963-1993: etiologic agents and their changing prevalence. Int J Dermatol 1994;33:548-9.
  14. Kuruvella T, Pandey S. Tinea Barbae. StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.
  15. Faergemann J. Management of seborrhoic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75-80.
  16. Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173-82.
  17. Saunte DML, Gaitanis G, Hay RJ. Malassezia-associated skin diseases, the use of diagnostics and treatment. Frontiers in cellular and infection microbiology 2020;10:article 112.
  18. Staats CC, Korstanje MJ. Fungi die onychomycosis veroorzaken in Nederland. Ned Tijdschr Geneeskd 1994;138:2340-3.
  19. Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patiënts. J Am Acad Dermatol 2009;61:242-6.
  20. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007;56:901-16.
  21. Sasagawa Y. Internal environment of footwear is a risk factor for tinea pedis. J Dermatol 2019;46:940-6.
  22. Şenel E, Doğruer Şenel S, Salmanoğlu M. Prevalence of skin diseases in civilian and military population in a Turkish military hospital in the central Black Sea region. J R Army Med Corps 2015;161:112-5.
  23. Cohen AD, Wolak A, Alkan M, SHalev R, Vardy DA. Prevalence and risk factors for tinea pedis in Israeli soldiers. Int J Dermatol 2005;44:1002-5.
  24. Klaassen KMG, Dulak MG, Van de Kerkhof PCM, Pasch MC. The prevalence of onychomycosis in psoriatic atients: a systematic review. J Eur Acad Dermatol Venereol 2014;28:533-41.
  25. Burzykowski T, Molenberghs G, Abeck D, Haneke E, Hay R, Katsambas A, et al. High prevalence of foot diseases in Europe: results of the achilles project. Mycoses 2003;46:496-505.
  26. Jones HE, Reinhardt JH, Rinaldi MG. Immunologic susceptibility to chronic dermatophytosis. Arch Dermatol 1974b;110:213-20.
  27. Hau CS, Tada Y, Kanda N, Watanabe S. Immunoresponses in dermatomycoses. J Dermatol 2015;42:236-44.
  28. Gupta AK, Taborda P, Taborda V, Gilmour J, Rachlis A, Salit I, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39:746-53.
  29. Tosti A, Hay R, Arenas-Guzmán R. Patiënts at risk of onychomycosis --risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005;19 Suppl 1:13-6.
  30. Saez de Ocariz MM, Arenas R, Ranero-Juarez GA, Farrera-Esponda F, Monroy-Ramos E. Frequency of toenail onychomycosis in atients with cutaneous manifestations of chronic venous insufficiency. Int J Dermatol 2001;40:18-25.
  31. Kulac M, Acar M, Karaca S, Cetinkaya Z, Albayrak R, Haktanir A, et al. Venous insufficiency in atients with toenail onychomycosis. J Ultrasound Med 2005;24:1085-9.
  32. Gupta AK, Gupta MA, Summerbell RC, Cooper EA, Konnikov N, Albreski D, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000b;14:466-9.
  33. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139:665-71.
  34. Robbins JM. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications 2003;17:98-104
  35. Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle diabetic foot study. Diabetes Care 2006;29:1202-7.
  36. Bosman A, Van Duin JM, Vos D, Van de Knaap L, Van de Hoek M. Hoofdschimmel: een nieuw probleem? Infectieziekten Bulletin 1997;8:11-2.
  37. Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A. Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis 2013;91:237-45.
  38. Timen A, Bovee L, Leentvaar-Kuijpers A, Peerbooms PG, Coutinho RA. Tinea capitis bij kinderen op de basisschoolleeftijd in Amsterdam Zuid-Oost: vooral Trichophyton tonsurans. Ned Tijdschr Geneeskd 1999;143:24-7.
  39. Ghannoum M, Isham N, Hajjeh R, Cano M, Al-Hasawi F, Yearick D, et al. Tinea capitis in Cleveland: survey of elementary school students. J Am Acad Dermatol 2003;48:189-93.
  40. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995;96:265-7.
  41. Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med 1999;153:483-6.
  42. Mancianti F, Nardoni S, Corazza M, D’Achille P, Ponticelli C. Environmental detection of Microsporum canis arthrospores in the households of infected cats and dogs. J Feline Med Surg 2003;5:323-8.
  43. Radentz WH. Fungal skin infections associated with animal contact. Am Fam Physician 1991;43:1253-6.
  44. Detandt M, Nolard N. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995;38:509-13.
  45. Lacroix C, Baspeyras M, De La Salmonière P, Benderdouche M, Couprie B, Accoceberry I, et al. Tinea pedis in European marathon runners. J Eur Acad Dermatol Venereol 2002;16:139-42.
  46. Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 2004;18:48-51.
  47. Jones HE, Reinhardt JH, Rinaldi MG. Acquired immunity to dermatophytes. Arch Dermatol 1974a;109:840-8.
  48. Van Vloten WA, Degreef HJ, Stolz E, Vermeer BJ, Willemze R. Dermatologie en venereologie. Amsterdam: Reed business, 2000.
  49. Kuijpers AF, Tan CS. Schimmels en gisten gevonden bij mycologische onderzoek van huid- en nagelinfecties in Nederland, 1992-1993. Ned Tijdschr Geneeskd 1996;140:1022-5.
  50. Velasquez-Agudelo V, Cardona-Arias JA. Meta-analysis of the utility of culture,
    biopsy, and direct KOH examination for the diagnosis of onychomycosis. BMC Infectious Diseaes 2017;17:166.
  51. De Kock CA, Sampers GH, Knottnerus JA. Diagnosis and management of cases of suspected dermatomycosis in The Netherlands: influence of general practice based potassium hydroxide testing. Br J Gen Pract 1995;45:349-51.
  52. Gustafson E, Bakotic W, Bennett L, Page L, McCarthy L. DNA-based detection for onychomycosis correlates better to histopathology than does fungal culture. Dermatol Online J 2019;25:13030/qt5bc2z46g.
  53. Bagatell FK. A prospective study of bifonazole 1% cream in the once-daily management of tinea corporis/cruris. Adv Ther 1986;3:294-300.
  54. Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007;CD001434.
  55. Del Palacio A, Ortiz FJ, Perez A, Pazos C, Garau M, Font E. A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in candida and dermatophyte skin infections. Mycoses 2001;44:173-80.
  56. Tanenbaum L, Anderson C, Rosenberg M, Dorr A. A new treatment for cutaneous candidiasis: sulconazole nitrate cream 1%. Int J Dermatol 1983;22:318-20.
  57. Niewerth M, Ciclopiroxolamine treatment effects. Antimicrob Agents Chemotherap 2003;47;1805-7.
  58. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox, recent nonclinical and clincical data relevant to its use as a topical antimycotic agent. Drugs 2010;70:2133-52.
  59. Aly R, Fisher G, Katz I, Levine N, Lookingbill DP, Lowe N, et al. Ciclopirox gel in the treatment of patiënts with interdigital tinea pedis. Int J Dermatol 2003;42 Suppl 1:29-35.
  60. Bogaert H, Cordero C, Ollague W, Savin RC, Shalita AR, Zaias N. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986;14:210-6.
  61. Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol 2005;44:590-3.
  62. Korting HC, Kiencke P, Nelles S, Rychlik R. Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis. Am J Clin Dermatol 2007;8:357-64.
  63. Polat AK, Belli AA, Alataş ET, Doğan G. Comparison of efficacy and safety of topical 1% butenafine and topical 1% ciclopirox olamine in the treatment of tinea pedis and evaluation of the effects on the quality of life of these treatmens: a randomized single-blind trial. Turk J Dermatol 2017;11:174-8.
  64. Gupta AK, Renaud HJ, Quinlan EM, Shear NH, Piguet V. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021 Mar;22(2):149-157. doi: 10.1007/s40257-020-00580-6. Epub 2020 Dec 22. PMID: 33354740
  65. Ebert A, Monod M, Salamin K et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses 2020;63:717-28.
  66. Nenoff P, Verma SB, Ebert A et al. Spread of Terbinafine-Resistant Trichophyton mentagrophytes Type VIII (India) in Germany-“The Tip of the Iceberg?”. J Fungi (Basel) 2020;6:207.
  67. Sacheli R, Harag S, Dehavay F et al. Belgian National Survey on Tinea Capitis: epidemiological considerations and highlight of terbinafine-resistant T. mentagrophytes with a mutation on SQLE gene. J Fungi (Basel) 2020;29;6:195.
  68. Bell-Syer SE, Hart R, Crawford F, Torgerson DJ, Tyrrell W, Russell I. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2002;CD003584.
  69. El-Gohary M, Van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, Moore M, Little P. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev 2014;CD009992.
  70. Lareb 2009. Addendum seleensulfide. Ga naar bron
  71. Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010;146:1132-40.
  72. Gupta AK, Foley KA. Antifungal Treatment for Pityriasis Versicolor. J Fungi (Basel) 2015;1:13-29.
  73. Muzaffar F, Ejaz A, Mahmood K. Determination of cost effective topical therapy for pityriasis versicolor. J Pak Assoc Dermatol 2008;18:159-164.
  74. Sharquie KE, Al-Hamamy HM, Noaimi AA, Al-Shawi IA. Treatment of pityriasis versicolor using 1% diclofenac gel and clotrimazole cream (comparative therapeutic study). Journal of the Saudi Society of Dermatology & Dermatologic Surgery 2011;15: 19-23.
  75. Sharma J, Kaushal J, Aggarwal K. A comparative study of efficacy and safety of eberconazole versus terbinafine in patiënts of tinea versicolor. Indian J Dermatol 2018;63:53-6.
  76. Rad F, Nik-Khoo B, Yaghmaee R, Gharibi F. Terbinafin 1% cream and ketoconazole 2% cream in the treatment of pityriasis versicolor: a randomized comparative clinical trial. Pak J Med Sci 2014;30:1273-6.
  77. Chopra V, Jain VK. Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor. Indian J Dermatol Venereol Leprol 2000;66:299-300.
  78. Innamuri R, Nayak S, Shenoi SD. Open comparative study of efficacy and safety of ketoconazole soap and oral ketoconazole in tinea versicolor. Journal of Pakistan Association of Dermatologists 2014;24:63-7.
  79. Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: a double-blind randomized controlled trial. J Dermatol 2010;37:699-702.
  80. Faergemann J. Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study. Mycoses 1988;31:377-9.
  81. Roseeuw D, Willemsen M, Kint RT, Peremans W, Mertens RL, Van Cutsem J. Itraconazole in the treatment of superficial mycoses—a double-blind study vs. placebo. Clin Exp Dermatol 1990;15:101-4.
  82. Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol 1996;34:785-7.
  83. Urcuyo FG, Zaias N. The successful treatment of pityriasis versicolor by systemic ketoconazole. J Am Acad Dermatol 1982;6:24-5.
  84. Savin RC. Systemic ketoconazole in tinea versicolor: a double-blind evaluation and 1-year follow-up. J Am Acad Dermatol 1984;10(5 Pt 1):824-30.
  85. Silva H, Gibbs D, Arguedas J. A comparison of fluconazole with ketoconazole, itraconazole, and clotrimazole in the treatment of patients with pityriasis versicolor. Current Therapeutic 1998;59:203-14.
  86. Del Palacio Hernanz A, Delgado Vicente S, Menéndez Ramos F, Rodríguez-Noriega Belaustegui A. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987;9 Suppl 1:S121-7.
  87. Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16:19-33.
  88. Faergemann J, Gupta AK, Al MA, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002;138:69-73.
  89. Crawford F, Young P, Godfrey C, Bell-Syer SE, Hart R, Brunt E, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002;138:811-6.
  90. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7.
  91. Roberts DT, Richardson MD, Dwyer PK, Donegan PK. Terbinafine in chronic paronychia and candida onychomycosis. J Dermatolog Treat 1992;3:39-42.
  92. Warshaw EM, Nelson D, Carver SM, Zielke GR, Webster N, Lederle FA, et al. A pilot evaluation of pulse itraconazole vs terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol 2005;44:785-8.
  93. Havu V, Brandt H, Heikkila H, Hollmen A, Oksman R, Rantanen T, et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br J Dermatol 1999;140:96-101.
  94. Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev 2020;1:CD012093.
  95. Gupta AK, Foley KA, Mays RR, Shear NH, Piguet V. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. Br J Dermatol 2020a;182:287-99.
  96. Gupta AK, Surprenant MS, Kempers SE, Pariser DM, Rensfeldt K, Tavakkol A. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: a randomized, multicenter, double-blind, vehicle-controlled phase 3 study. J Am Acad Dermatol 2021b.
  97. Baran R, Tosti A, Hartmane I, Altmeyer P, Hercogova J, Koudelkova V, Ruzicka T, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009;23:773-81.
  98. Dars S, Banwell HA, Matricciani L. The use of urea for the treatment of onychomycosis: a systematic review. J Foot Ankle Res 2019;1;12:22.
  99. Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses 2012;55:532-40.
  100. Jennings MB, Pollak R, Harkless LB, Kianifard F, Tavakkol A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc 2006;96:465-73.
  101. Bassiri-Jahromi S, Houshang Ehsani A, Mirshams-Shahshahani M, Jamshidi B. A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial. J Dermatolog Treat, 2012 Dec;23(6):453-6. doi: 10.3109/09546634.2011.588191. Epub 2011 Jul 24.
  102. Yeung K, Ortner VK, Martinussen T, Paasch U, Haedersdal M. Efficacy of laser treatment for onychomycotic nails: a systematic review and meta-analysis of prospective clinical trials. Lasers Med Sci 2019;34:1513-25.
  103. Sabbah L, Gagnon C, Bernier FE, Maari C. A randomized, double-blind, controlled trial evaluating the efficacy of Nd:YAG 1064 nm short-pulse laser compared with placebo in the treatment of toenail onychomycosis. J Cutan Med Surg 2019;23:507-12.
  104. El-Tatawy RA, Aliweh HA, Hegab DS, Talaat RAZ, Shams Eldeen MA. Fractional carbon dioxide laser and topical tioconazole in the treatment of fingernail onychomycosis. Lasers Med Sci. 2019;34:1873-1880.
  105. Zaki AM, Abdo HM, Ebadah MA, Ibrahim SM. Fractional CO2 laser plus topical antifungal versus fractional CO2 laser versus topical antifungal in the treatment of onychomycosis. Dermatol Ther 2020;33:e13155
  106. Xu Y, Miao X, Zhou B, Luo D. Combined oral terbinafine and long-pulsed 1,064-nm Nd: YAG laser treatment is more effective for onychomycosis than either treatment alone. Dermatol Surg 2014;40:1201-7.
  107. Nijenhuis-Rosien L, Kleefstra N, Van Dijk PR, Wolfhagen M, Groenier KH, Bilo HJG, et al. Laser therapy for onychomycosis in patients with diabetes at risk for foot ulcers: a randomized, quadruple-blind, sham-controlled trial (LASER-1). J Eur Acad Dermatol Venereol 2019;33:2143-50.
  108. Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol 2014;70:911-7.
  109. Karsai S, Jäger M, Oesterhelt A, Weiss C, Schneider SW, Jünger M, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. J Eur Acad Dermatol Venereol 2017;31:175-80.
  110. El-Tatawy RA, Abd El-Naby NM, El-Hawary EE, Talaat RA. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. J Dermatolog Treat 2015;26:461-4.
  111. Kim TI, Shin MK, Jeong KH, Suh DH, Lee SJ, Oh IH, Lee MH. A atients d comparative study of 1064 nm Neodymium-doped yttrium aluminium garnet (Nd:YAG) laser and topical antifungal treatment of onychomycosis. Mycoses 2016;59:803-810.
  112. Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004;5:225-37
  113. Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics 2004;114:1312-5.
  114. Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Stewart D, et al. Terbinafine in the treatment of trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics 2002;109:602-7.
  115. Jahangir M, Hussain I, Ul Hasan M, Haroon TS. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998;139:672-4.
  116. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
  117. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996;35:591-3.
  118. Bergstresser PR, Elewski B, Hanifin J, Lesher J, Savin R, Shupack J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993;28:648-51.
  119. Budimulja U, Paul C. One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. J Dermatolog Treat 2002;13:39-40.
  120. Elewski B, Pariser D, Rich P, Scher RK. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg 2013;32(2 Suppl 1):S9-12.
  121. Evans EGV, James IGV, Seaman RAJ, Richardson MD. Does naftifine have anti‐inflammatory properties? A double‐blind comparative study with 1% clotrimazole/1% hydrcortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993;129:437‐42.
  122. Kligman AM. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther 1985;7:409-17.
  123. Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984;11:235-8.
  124. Tschen EH, Bucko AD, Oizumi N, Kawabata H, Olin JT, Pillai R.J. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. Drugs Dermatol 2013;12:186-92.
NHG-werkgroep:
Van Balen J, Claassen N, Greving J en Wiersma T.
E-mail